TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03481036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Direct Acting Antivirals
Description: Sofosbuvir and Daclatasvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAAs in Cirrhotics Genotype 2/3
Description: Sofosbuvir and Daclatasvir with weight based ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAAs in Cirrhotics Genotye 1,4,5,6
Description: Sofosbuvir and Ledipasvir with weight based ribavirin
Study: NCT00540514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound paclitaxel
Description: Administered by intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate \[GFR\] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate \[GFR\] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
Study: NCT01740986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA09012 Low dose
Description: Tablet, b.i.d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SA09012 High dose
Description: Tablet, b.i.d
Study: NCT04472117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: usual care
Description: Interviews will be conducted in person or by telephone by an MD on the research team who does not have an ongoing treatment relationship with the patient, and has been trained by the qualitative methods specialist. Interviews will take place over the phone or in person and are anticipated to last approximately 20-30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Watch an educational video created by the research team and.will also complete the post-video survey. Those randomized to view the video must complete the post-video survey (Appendix 3), and all patients must complete the Post-Op Survey with the Patient Experience and Decision Regret Scale (Appendix 5) to be evaluable. If not completed, they will be replaced.
Study: NCT01740986

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, b.i.d
Study: NCT04012385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counseling
Description: Nutritional plan and Physical activity goals
Study: NCT02625272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A
Description: The novel hand-assisted laparoscopic surgery with complete mesocolic excision and central vascular ligation for right colon cancer. In this group, greater omentum, transverse colon, and ileum were brought out through the hand-port incision at the beginning of the operation and divided extracorporeally.
Study: NCT02656121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 6000 IU of vitamin D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovulatory Agent
Description: only Clomophine Citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovulatory Agent
Description: only Clomophine Citrate
Study: NCT00516893

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG00002-E (natalizumab high titer)
Study: NCT01925495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: varied middle-ear pressure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varied middle-ear gas composition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: varied ear-canal pressure
Study: NCT00355537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Sustanon- intramuscular testosterone 200mg every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Saline injection intramuscular every 2 weeks
Study: NCT01428037

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet vaginal inserted at 4 hrly interval with maximum of three doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal Tablet 25 mcg
Description: One tablet vaginal insert at 4 hrly interval with maximum of three doses
Study: NCT00728208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK372475
Description: 1.5mg for 28 days
Study: NCT01144975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XOMA 052
Description: Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
Study: NCT04014881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Third-generation anti-CD123 CAR-T cells
Description: From the minimum dose, If no DLT emerges in the group, then the next group uses the subsequent higher dose. If DLT emerges in a single subject in any dose level, 3 more subjects will be enrolled to the same dose level.
Study: NCT01941979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
Study: NCT00583414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair
Description: Endovascular exclusion of aneurysm
Study: NCT06326619

Intervention type: PROCEDURE
Intervention: Primary tumor resection
Description: In addition to systemic therapy a primary tumor resection was performed.

Intervention type: PROCEDURE
Intervention: Systemic Therapy
Description: chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis

Intervention type: PROCEDURE
Intervention: Systemic Therapy
Description: chemotherapy, antibody, or immunotherapy (alone or in combination) starting within 12 months after diagnosis
Study: NCT00814697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Coil Stimulation (rTMS)
Description: The first six patients were administered rTMS at 10Hz in 20 trains of 5 seconds with 20 second intervals between trains in each hemisphere. The total number of pulses for each session was set at 1000 pulses. The second six enrolled patients were administered rTMS at 15 Hz in 20 trains of 5 seconds with 25 second intervals between trains in each hemisphere.
Study: NCT00002938

Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional surgery
Description: Salvage prostatectomy
Study: NCT02419196

Intervention type: OTHER
Intervention: Perioperative pulmonary function tests
Description: Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day

Intervention type: OTHER
Intervention: Perioperative pulmonary function tests
Description: Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day

Intervention type: OTHER
Intervention: Perioperative pulmonary function tests
Description: Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day
Study: NCT02795507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabit-Tec System
Description: Device with visual and kinesthetic feedback

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabit-Tec System
Description: Device without visual and kinesthetic feedback

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional exercises
Study: NCT00731653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Product: BCI-024 + BCI-049
Description: BCI-024 and BCI-049 once a day at bedtime for 6 weeks
Study: NCT04465032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gut microbiome transplantation
Description: Fecal transplantation will be performed at baseline and at week 3 and 6. At the Department of Clinical Bacteriology either the autologous or allogenic feces is prepared for donation by an experienced lab co-worker. The fecal transplantation will be performed via gastroduodenal endoscopy at the Department of Gastroenterology by an experienced endoscopist. To alleviate the procedure, midazolam is offered to the participants. Following placement of the endoscope in the horizontal duodenum, 150 mL feces solution is inserted via the endoscope.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gut microbiome transplantation
Description: Fecal transplantation will be performed at baseline and at week 3 and 6. At the Department of Clinical Bacteriology either the autologous or allogenic feces is prepared for donation by an experienced lab co-worker. The fecal transplantation will be performed via gastroduodenal endoscopy at the Department of Gastroenterology by an experienced endoscopist. To alleviate the procedure, midazolam is offered to the participants. Following placement of the endoscope in the horizontal duodenum, 150 mL feces solution is inserted via the endoscope.
Study: NCT03788018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine and dexmedetomidine IV
Description: Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine and dexmedetomidine IV
Description: Patients received IV bolus infusion of lidocaine (2%) 1.5 mg/kg and dexmedetomidine 0.5 µg/kg diluted with normal saline to 20 ml in the LD group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion at rate of lidocaine 1.5 mg/kg and dexmedetomidine 0.4 µg/kg made up to 20 mL every hour until 30 min before the end of operation, respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline IV
Description: Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline IV
Description: Patients received 20 ml normal saline and 20 ml normal saline in the CON group respectively, over 10 minutes before induction of anesthesia, followed by a continuous IV infusion 20 ml normal saline and 20 ml normal saline every hour until 30 min before the end of surgery
Study: NCT04509518

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise therapy program plus TENS therapy
Description: All patients were receiving the same physical therapy exercise program, 3 times per week for 12 weeks in the form of pelvic floor relaxation exercises, diastasis correction exercises , myofascial trigger points release, connective tissue manipulation and progressive abdominal strengthening exercises. Pelvic floor relaxation exercises included pelvic floor release stretches, Proprioceptive Neuromuscular Facilitation technique, and pelvic floor drop exercises in addition to TENS therapy The standard protocol for TENS therapy in this group was 20 minutes of 100 Hz frequency, pulse duration of 200 µsec, three times a week for successive 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy program plus TENS therapy
Description: All patients were receiving the same physical therapy exercise program, 3 times per week for 12 weeks in the form of pelvic floor relaxation exercises, diastasis correction exercises , myofascial trigger points release, connective tissue manipulation and progressive abdominal strengthening exercises. Pelvic floor relaxation exercises included pelvic floor release stretches, Proprioceptive Neuromuscular Facilitation technique, and pelvic floor drop exercises in addition to TENS therapy The standard protocol for TENS therapy in this group was 20 minutes of 100 Hz frequency, pulse duration of 200 µsec, three times a week for successive 12 weeks
Study: NCT00301600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: MMF,1.0g/d
Study: NCT01468207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pre-filled syringe, administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo pre-filled syringe, administered by subcutaneous injection
Study: NCT01713361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-FXIRx Dose #2
Description: Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS-FXIRx Dose #3
Description: Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). \[Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.\]
Study: NCT01225965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ectoin Inhalation Solution
Description: Once daily inhalation of Ectoin Inhalation Solution

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily inhalation of Placebo Inhalation Solution
Study: NCT01938508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
Study: NCT04200443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT00866034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide (Ovarian stimulation)
Description: Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide (Ovarian stimulation)
Description: Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.
Study: NCT04778163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical use of humor
Description: Clinical study in psychiatry in young adult patients between 18 and 25 years old. The aim of the study is to evaluate the therapeutic impact of the clinical use of humor through 6 group sessions (group of 5 to 10 patients), at the rate of one hour session per week for 6 weeks.~The investigators will form 2 groups of 5 to 10 patients matched in terms of gender, education level and score on a scale measuring their sense of humor. The participants will be asked to complete a series of tests measuring their ability to use humor, psychiatric symptoms and well-being.
Study: NCT01700725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal Irrigation - Saline
Description: Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the saline solution by themselves using the study-provided kit which will include packets of salt powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 2% buffered saline solution. The solution is then delivered to the nasal cavity using neti pot.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Irrigation - Xylitol
Description: Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the Xylitol solution by themselves using the study-provided kit which will include packets of Xylitol powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 5% Xylitol solution. The solution is then delivered to the nasal cavity using neti pot.
Study: NCT04784949

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: portland cement
Description: pulpotomy with PRF and white Portland cement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate
Description: pulpotomy with PRF and white Mineral trioxide aggregate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: pulpotomy with PRF and Biodentine
Study: NCT00758212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesotherapy
Description: The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.The diluted vaccine will be given intra-dermally using Mesotherapy,namely multiple injections given at one time in the torso, back and axillae.
Study: NCT01534871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Subjects will be enrolled in a 12-week community cardiac rehabilitation program. The program consists of two one hour exercise sessions per week and one one hour education session per week. For the exercise sessions the subjects will perform aerobic exercise at 60-80% of heart rate reserve. Education sessions will cover heart healthy eating, setting health-related goals, exercise, nutrition, healthy weight, medication, smoking cessation and stress/coping.
Study: NCT00311610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SN-38 liposome
Description: 38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
Study: NCT03355521

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic Walking
Description: Nordic walking Training the total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic Walking
Description: Nordic walking Training the total period of training was composed by 9-week of walking with poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free Walking
Description: Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free Walking
Description: Free walking Training The total period of training was composed by 9-week of walking without poles, two sessions per week. The cycles were divided into four microcycles composed of three training sessions. Each training session took 60 min. Free walking aerobics training was used during the training period. These exercises were performed alternating volume and intensity. The training session was divided into three stages: (a) stretching, joint mobility, and heating; (b) main part (FW); (c) return to the calm and ultimate stretching.
Study: NCT02371551

Intervention type: OTHER
Intervention: Blood/urine sampling
Description: Routine chemistry profile

Intervention type: OTHER
Intervention: Conventional routine CT examination
Description: Standard diagnostic examination

Intervention type: OTHER
Intervention: Contrast-enhanced renal ultrasonography (CEUS)
Description: Study-specific diagnostic examination

Intervention type: OTHER
Intervention: Functional MRI
Description: Study-specific diagnostic examination